ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Exploring spinal degenerative diseases therapy targets through druggability genes: a Mendelian randomization study.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
As society ages, the prevalence of spinal degenerative diseases (SDDs) is rising, creating significant life and financial burdens for patients and their families. This study employs mendelian randomization (MR) to identify therapeutic targets for SDDs management. Two sample mendelian randomization (TSMR) analyses were conducted to investigate the causal relationships between multiple genes and various SDDs, including osteoporosis (OP), spinal canal stenosis (SCS), and prolapsed disc/slipped disc (PD/SD). To enhance the robustness of the findings, summary data-based MR (SMR) analyses were performed, complemented by Bayesian co-localization, which provided strong evidential support for the results. Additionally, the potential therapeutic applications were assessed through estimates of druggability. Our findings reveal several target genes linked to the risk of SDDs. Notably, ESR1 was positively and causally associated with the risk of osteoporosis (OR: 1.011, 95% CI: 1.008-1.016, P
Indexed as
Identifiers
41922821What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.